Securities code: 300199 securities abbreviation: Hybio Pharmaceutical Co.Ltd(300199) Announcement No.: 2022-006
Hybio Pharmaceutical Co.Ltd(300199)
Announcement on abnormal fluctuations in the company's stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special tips:
1, the company and the Institute of Microbiology of China Academy of Sciences cooperate to develop New Coronavirus polypeptide nasal spray drug. In addition, we need to carry out many links including COVID-19 virus and its variants in live toxicity test, preclinical research, clinical research, pharmaceutical research and market promotion.
2. At present, there are covid-19 preventive and therapeutic drugs in different R & D stages in the world. Many covid-19 vaccines have been put on the market in China, and many antibodies and small molecule drugs are also in different R & D stages. There is uncertainty in the market competition pattern after the new drug is put on the market;
3. Affected by the development and control of overseas epidemic situation, the choice of drug use, overseas market promotion and other factors, there is still uncertainty whether the clinical trial application and products can be successfully approved for listing;
In the first three quarters of 2021, the company achieved an operating revenue of 507.7272 million yuan, a decrease of 26.15% over the same period last year, a net profit attributable to shareholders of listed companies of -118.0717 million yuan, a decrease of 311.20% over the same period last year, an asset liability ratio of 58.65%, and a high asset liability ratio. The company's share price has increased greatly in the short term, but the production and operation situation has not changed significantly. The company solemnly reminds the majority of investors to pay attention to the transaction risk of the secondary market, make prudent decisions and invest rationally. 1、 Abnormal fluctuations in stock trading
Hybio Pharmaceutical Co.Ltd(300199) (hereinafter referred to as "the company") has accumulated more than 30% of the deviation from the closing price increase for three consecutive trading days (January 13, 2022, January 14, 2022 and January 17, 2022). According to the relevant provisions of the special provisions on GEM trading of Shenzhen Stock exchange, it belongs to the abnormal fluctuation of stock trading.
2、 Description of the company's concern and verification
In view of the abnormal fluctuation of the company's stock trading, the board of directors of the company verified the controlling shareholders, actual controllers, all directors, supervisors and senior managers of the company through telephone and on-site inquiry. The relevant information is described as follows:
1. After verification, there is no need to correct or supplement the information disclosed by the company in the early stage;
2. After verification, the company has not found any unpublished material information that may or has had a great impact on the company's stock trading price reported by the public media recently;
3. After verification, the company's current production and operation is normal, and the internal and external business environment has not changed significantly; 4. After verification, the controlling shareholders and actual controllers of the company do not have any major events that should be disclosed but not disclosed by the company, or major events in the planning stage;
5. It is verified that during the period of abnormal stock fluctuation, the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell stocks;
6. The company has no other circumstances in violation of the provisions on fair information disclosure;
7. Other matters to be explained:
(1) On November 12, 2021, the company held the 37th meeting of the Fourth Board of directors, The bill was passed through the "motion on technology transfer contract with the Institute of Microbiology of China Academy of Sciences". China's China Securities Regulatory Commission announced the announcement of the Hybio Pharmaceutical Co.Ltd(300199) website on New Coronavirus polypeptides nasal spray in collaboration with the Institute of Microbiology, CAS.
(2) On December 25, 2021, the third meeting of the Fifth Board of directors and the second meeting of the Fifth Board of supervisors of the company deliberated and adopted the proposal on the change of accounting methods of joint-stock companies. For details, see Hybio Pharmaceutical Co.Ltd(300199) announcement on the change of accounting methods of joint-stock companies disclosed on the gem designated information disclosure website of CSRC in the same period.
(3) On December 29, 2021, the company issued the suggestive announcement on terlipressin for injection passing the conformity evaluation of generic drugs.
(4) On January 14, 2022, the company issued the suggestive announcement on the conformity evaluation of atoxiban acetate injection through generic drugs.
3、 Is there any explanation that should be disclosed but not disclosed
The board of directors confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange or the planning and intention related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange Information that may have a great impact on the trading price of the company's shares and their derivatives.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2, the company and the Institute of Microbiology of China Academy of Sciences cooperate to develop New Coronavirus polypeptide nasal spray drug. In addition, we need to carry out many links including COVID-19 virus and its variants in live toxicity test, preclinical research, clinical research, pharmaceutical research and market promotion.
3. At present, there are covid-19 preventive and therapeutic drugs in different R & D stages in the world. Many covid-19 vaccines have been put on the market in China, and many antibodies and small molecule drugs are also in different R & D stages. There is uncertainty in the market competition pattern after the new drug is put on the market;
4. Affected by the development and control of overseas epidemic situation, the choice of drug use, overseas market promotion and other factors, there is still uncertainty whether the clinical trial application and products can be successfully approved for listing;
5. In the first three quarters of 2021, the company achieved an operating revenue of 507.7272 million yuan, a decrease of 26.15% over the same period last year, a net profit attributable to shareholders of listed companies of -118.0717 million yuan, a decrease of 311.20% over the same period last year, an asset liability ratio of 58.65%, and a high asset liability ratio. The company's share price has increased greatly in the short term, but the production and operation situation has not changed significantly. The company solemnly reminds the majority of investors to pay attention to the transaction risk of the secondary market, make prudent decisions and invest rationally.
6. The information disclosure media designated by the company are securities times, China Securities News, Shanghai Securities News, securities daily and cninfo. Com. All information of the company shall be subject to the information published in the above designated media.
It is hereby announced.
Hybio Pharmaceutical Co.Ltd(300199) board of directors January 18, 2022
